Recent advances in melanoma staging and therapy

Annals of Surgical Oncology

Volumn 6, Issue 5, 1999, Pages 467-475

  McMasters, Kelly M ^a,e   Sondak, Vernon K ^b   Lotze, Michael T ^c   Ross, Merrick I ^d  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Adjuvant therapy; Gene therapy; Immunotherapy; Melanoma; Sentinel lymph node

Indexed keywords

ALPHA2B INTERFERON; INTERLEUKIN 2; MELANOMA VACCINE; MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DENDRITIC CELL; DRUG MEGADOSE; ELECTIVE SURGERY; GENE THERAPY; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; ULCER;

BIOPSY; CHEMOTHERAPY, ADJUVANT; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 0032799688     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0467-8     Document Type: Article

References (40)

1. Buzaìd AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer Staging System for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-51.
2. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
3. Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Cancer 1978; 41:948-56.
4. Balch CM, Soong S-J, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
5. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351:793-6.
6. Balch CM, Ross M, Soong S-J, Harrison R. Long-term results of a prospective, randomized trial involving elective regional lymph node dissection in patients with intermediate thickness melanomas. Abstract 3. Presented at the 52nd Annual Cancer Symposium of the Society of Surgical Oncology, Orlando, FL, March 5, 1999.
7. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
8. Morton DL, Wen DR, Foshag LJ, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanoma of the head and neck. J Clin Oncol 1993;11:1751-6.
9. Ross MI, Reintgen D, Balch CM. Selective lymphadenectomy: Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993;9:219-23.
10. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.
11. Miliotes G, Albertini J, Berman C, et al. The tumor biology of melanoma nodal metastases. Am Surg 1996;62:81-8.
12. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253-60.
13. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217-24.
14. Glass LF, Messina JL, Cruse W, et al. The use of intraoperative radiolymphoscintigraphy for sentinel lymph node biopsy in patients with malignant melanoma. Dermatol Surg 1996;22:715-20.
15. Kapteijn BAE, Nieweg OE, Liem I, et al. Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 1997;4:156-60.
16. Van Der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994;81:1769-70.
17. Ramnath EM, Kamath D, Brobeil A, et al. Lymphatic mapping for melanoma: Long term results of regional nodal sampling with radioguided surgery. Cancer Control: Journal of the Moffitt Cancer Center 1997;4:483-90.
18. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-8.
19. Leong SPL, Steinmetz I, Habib FA, et al. Optimal selective sentinel lymph node dissection in primary melanoma. Arch Surg 1997;132:666-73.
20. Mudun A, Murray DR, Herda SC, et al. Early stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. Radiology 1996;199:171-5.
21. Balch CM, Cascinelli N, Sim FH, et al. Elective lymph node dissection: results of prospective randomized trials. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. St. Louis: Quality Medical Publishing, 1998:405-18.
22. Wang X, Heller R, VanVoorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-74.
23. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280: 1410-5.
24. Mellado B, Colomer D, Castel T, et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 1996;14:2091-7.
25. Morton DL, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970;68:158-64.
26. Sondak VK, Wolfe JA. Adjuvant therapy of melanoma. Curr Opin Oncol 1997;9:189-204.
27. Sondak VK, Kopecky KJ, Smith JW II, et al. Is interferon-γ detrimental? Results of a Southwest Oncology Group randomized trial of adjuvant human interferon-γ versus observation in malignant melanoma. In: Salmon SE, ed. Adjuvant Therapy of Cancer VIII. Philadelphia: Lippincott-Raven, 1997:259-72.
28. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;1 3:2776-83.
29. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:7-17.
30. Kirkwood JM, Ibrahim J, Sondak V, et al. Role of high-dose IFN in high-risk melanoma: Preliminary results of the E1690/S9111/ C9190 US Intergroup postoperative adjuvant trial of high and low-dose IFNα2b (HDI and LDI) in resected high-risk primary or regionally lymph node metastatic melanoma in relation to 10-year updated results of E1684. Abstract. Presented at the Advances in the Biology and Treatment of Cutaneous Melanoma Meeting, Boston, November 7, 1998.
31. Belli F. Low dose interferon α2a as adjuvant treatment after radical node dissection for cutaneous melanoma. Update of WHO Melanoma Programme trial 16. Proc Soc Surg Oncol 1998;51:8.
32. Rusciani L, Petraglia S, Alotto M, Calvieri S, Vezzoni G. Post-surgical adjuvant therapy for melanoma: evaluation of a 3-year randomized trial with recombinant interferon-a after 3 and 5 years of follow-up. Cancer 1997;79:2354-60.
33. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425-9.
34. Grob JJ, Dreno B, Delaunay M, et al. Long-term results of adjuvant therapy with low dose interferon-a2a in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Abstract. Proc Am Soc Clin Oncol 1998;17:514a.
35. Haluska FG. Adjuvant interferon for stage II melanoma. J Clin Oncol 1998;16:3205-6.
36. Buzaid AC, Bedikian A, Houghton AN. Systemic chemotherapy and biochemotherapy. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. St. Louis: Quality Medical Publishing, 1998:405-18.
37. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13:910-3.
38. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability if complete responses with metastatic cancer treated with high-dose interleukin-2. Ann Surg 1998;228:307-19.
39. Keilholz U, Conradt C, Legha SW, et al. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 1998;16:2921-9.
40. Lotze MT, Shurin M, Davis I, et al. Dendritic cell based therapy of cancer. Adv Exp Med Biol 1997;417:551-69.